Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

Vanna Chiarion-Sileni; Paola Del Bianco; Antonella Romanini; Michele Guida; Adriano Paccagnella; Maurizio Dalla Palma; Emanuele Naglieri; Ruggero Ridolfi; Barbara Silvestri; Maria Michiara; Gian Luca De Salvo

doi:10.1186/1471-2407-6-44

Email this article to a friend

Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

Vanna Chiarion-Sileni^*, Paola Del Bianco, Antonella Romanini, Michele Guida, Adriano Paccagnella, Maurizio Dalla Palma, Emanuele Naglieri, Ruggero Ridolfi, Barbara Silvestri, Maria Michiara and Gian Luca De Salvo

* Corresponding author: Vanna Chiarion-Sileni mgaliz@tiscali.it

BMC Cancer 2006, 6:44 doi:10.1186/1471-2407-6-44

BMC Cancer

Viewing options

Associated material

Tools

Share this article

Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

BMC Cancer

Viewing options

Associated material

Related literature

Cited by

Other articles by authors

Related articles/pages

Tools

Share this article

Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]